Biophan to Present Technology Solutions at the In3 Medical Devices Summit
Mr. Jeffrey Helfer, President, Cardiovascular Division and Vice President of Engineering of Biophan Technologies, will present in the Cardiovascular and Peripheral Vascular Diagnostics & Therapeutics track at 2:00 pm PT on June 22, 2006. Mr. Helfer will provide an overview of the MYO-VAD(TM), a novel, MRI-compatible ventricular assist device (VAD) that addresses the $7.1 billion worldwide market opportunity for cardiac assist devices. The MYO-VAD(TM) has significant potential to improve the treatment of many forms of acute and chronic heart disease.
“The In3 Medical Devices Conference provides an excellent forum for Biophan to present its MYO-VAD(TM) ventricular assist device and our nanotechnology-based drug delivery solutions. The MYO-VAD(TM) is a breakthrough ventricular assist device, which does not contact circulating blood, and therefore reduces the risks of clotting and stroke, bleeding, and infection.”
Mr. Michael Weiner, Biophan CEO, will present in the Other High-Growth Technologies: Drug Delivery track at 11:40 am PT on June 22, 2006. Mr. Weiner will provide an overview of Nanolution's work developing advanced nanotechnology-based drug delivery devices and drug-elution technologies for the $40 billion drug-delivery marketplace. "Our Nanolution technology has significant potential to enable controlled release of drugs, on demand, from coatings on medical devices such as stents and orthopedic implants. The Nanolution technologies are also applicable for enhancing the repurposing of FDA approved drugs for new indications, improving the safety and specificity of pharmaceuticals. We are expanding the staff and goals of this division and feel it can contribute to shareholder value for Biophan, leveraging our valuable intellectual property assets in this arena," Mr. Weiner said.
Mr. Wiener will be available to field on questions on Biophan's innovative technologies at both the breakout sessions and the meeting that will take place at the In3 Medical Devices Summit.
Mr. Weiner stated, "The In3 Medical Devices Conference provides an excellent forum for Biophan to present its MYO-VAD(TM) ventricular assist device and our nanotechnology-based drug delivery solutions. The MYO-VAD(TM) is a breakthrough ventricular assist device, which does not contact circulating blood, and therefore reduces the risks of clotting and stroke, bleeding, and infection."
About the In3 Medical Devices Summit
The In3 Medical Device Summit is the most important venue of its kind for previewing cutting-edge emerging medical technology companies and for engaging with the biggest dealmakers in the industry, including senior executives from the device industry and healthcare investment community, all in a short period of time. All attendees will benefit from the mix of quality presentations, speakers, roundtables, workshops and panels addressing the hottest topics in the ever-more competitive and lucrative medical technology marketplace, along with the unmatched networking and partnering opportunities that attendees have come to expect from Investment In Innovation (In3) events over the past 5 years. For more information please visit www.meddevicesummit.com.
Biophan develops and markets cutting-edge technologies for the medical device industry that provide competitive advantages. The Company's founding goal was to make all biomedical devices capable of safely and successfully working with magnetic resonance imaging (MRI), problems which the Company has solved and begun to license to leading device manufacturers. The Company's mission has expanded to provide other technologies which will improve the delivery of healthcare. Biophan's technologies enable medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and implants such as stents to be safely and/or effectively imaged under MRI. The Company is helping to commercialize the MYO-VAD(TM), a novel, MRI-compatible ventricular assist device which has significant potential to improve the treatment of many forms of acute and chronic heart disease. Other applications in development include drug delivery and power systems which derive energy from body heat. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of over 200 U.S. and foreign patents, licenses, or applications. This total includes 56 issued U.S. patents, and over 100 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials, and photonics. Biophan has joint development and licensing agreements with Boston Scientific Corporation and NASA's Ames Center for Nanotechnology. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN.
For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.